Latest News | Biocon to Acquire Debentures of Biocon Biologics from Goldman Sachs for USD 198.5 Mn

New Delhi, Jun 26 (PTI) Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of its arm Biocon Biologics Ltd from Goldman Sachs for USD 198.5 million.

The board of directors, at its meeting held on June 26, 2025, approved the acquisition of optionally convertible debentures (OCDs) of Biocon Biologics Ltd, an unlisted subsidiary, from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and Goldman Sachs India AIF Scheme-1 (Goldman Sachs), Biocon Ltd said in a regulatory filing.

Also Read | What Are the New Metro Compensation Rules in India? Ministry of Housing and Urban Affairs Enhances Payouts for Death and Severe Injuries; Check Details.

The parties have entered into an agreement under which Biocon will "purchase 1,125 unlisted, unsecured, redeemable, optionally convertible debentures (OCDs) of Biocon Biologics of the face value of Rs 1 crore each for a consideration of rupee equivalent to USD 198.5 million, which may be varied depending on the date of purchase", it added.

Under the agreement, the company will acquire 1,047 OCDs from Goldman Sachs India Alternative Investment Trust AIF Scheme 2 and 78 OCDs from Goldman Sachs India AIF Scheme-1, it added.

Also Read | Is June 27 Public Holiday in Odisha for Jagannath Puri Rath Yatra? Will Schools and Banks Remain Open or Closed? All You Need To Know.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)